Diagnosing PPF and the Importance of Early Detection
Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses how progressive pulmonary fibrosis is diagnosed in clinical practice, the barriers hindering early diagnosis, strategies to overcome these challenges and the critical role of early detection and intervention in improving patient outcomes and reducing long-term healthcare costs.
Video content above is prompted by the following:
- How is progressive pulmonary fibrosis (PPF) diagnosed in clinical practice?
- What barriers hinder early diagnosis, and what strategies can be implemented to address these barriers?
- What is the role of early diagnosis and intervention in improving patient outcomes in PPF?
- How can early detection and intervention reduce long-term healthcare costs for patients?
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
